We’re delighted to announce our investment in Bastion Therapeutics, a preclinical biotechnology company focused on restoring immune balance. In a funding round led by NG Bio, a specialist immunology and inflammatory diseases investor and venture builder, Pioneer Group joined early-stage life sciences investors Wren Capital and Deep Science Ventures. The total launch funding secured was $840,000.
Bastion has already generated significant preclinical data, which validates its platform Treg engineering technology. The Company will utilise the new financing to build its research capabilities, continue product development towards the clinical development stage, and open laboratory space in London.
Tregs are a vital component of the human immune system, which naturally regulates inflammation in healthy individuals. In patients suffering from chronic inflammatory and autoimmune conditions, the immune function is dysregulated, and Tregs fail to control the excessive inflammation.
Bastion’s GRIT™ platform technology utilises genetic engineering to restore and enhance the patient’s Treg function while also targeting Tregs to specific sites of tissue inflammation. Bastion’s vision is to provide curative treatments that can transform patients’ lives rather than alleviate the symptoms of inflammatory disorders and autoimmune diseases.
Nuno Madeira do Ó, Co-Founder and CEO of Bastion Therapeutics: “We are very excited to have secured financing to complete the preclinical testing of our groundbreaking platform technology and to advance our first therapeutic product towards the clinical development stage.”
“We are fortunate to have the support of a group of highly successful life sciences investors who share Bastion’s vision to achieve a curative treatment for inflammatory disorders and autoimmune diseases.”
Glenn Crocker, Executive Director & Head of Ventures at Pioneer Group: “Bastion Therapeutics’ innovative technology and unwavering commitment to developing advanced therapies for inflammatory conditions align perfectly with our mission to foster innovation in biotechnology.”
We are confident that Bastion Therapeutics’ approach will significantly impact the lives of patients in need and pave the way for a new era of Treg cell therapies. We look forward to seeing the Company progress.”
About Bastain Therapeutics
Bastion Therapeutics is a preclinical stage biotechnology company leveraging proprietary platform technology to restore the function of Tregs in patients with a dysregulated immune condition.
Bastion’s technology has been conceived and developed to overcome challenges associated with previous generations of Treg therapies. The company’s vision is to provide life-changing, curative therapies for patients suffering from inflammatory disorders and autoimmune diseases.
Tregs can deliver a range of therapeutic benefits in a single treatment, effectively addressing the intricate and multifaceted nature of inflammatory disorders. Bastion Therapeutics’ proprietary GRIT™ platform technology (Genetically Reconfigured & Improved Treg) unlocks the full potential of Tregs by addressing the fundamental challenges that have limited previous generations of Treg cell therapies. Engineered with GRIT™ technology, Tregs can target active inflammation at tissues of interest with high specificity, suppress dysregulated immune responses, reinforce Treg phenotype stability within inflammatory microenvironments, and promote tissue repair and regeneration.
Bastion Therapeutics is focused on developing pioneering, best-in-class Treg cell therapies that can target the root causes of inflammatory disorders and provide long-term relief for patients. The Company is committed to addressing a wide range of inflammatory disorders, encompassing both neuroinflammatory and peripheral conditions, through their innovative Treg cell therapies. Bastion’s pipeline strategy comprises both autologous and allogeneic Treg cell therapies designed to restore immune balance with remarkable precision.
For more information about Bastion Therapeutics, please visit www.bastion-tx.com.
